Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients
NCT ID: NCT02190864
Last Updated: 2015-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
210 participants
OBSERVATIONAL
2013-12-31
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 1: Determine whether individual patients' preferences, characteristics, and treatment experiences affect the definition of treatment success.
Aim 2: Determine how to best predict real-life patients' treatment choices based on patients' preferences of adverse events.
Aim 3: Determine whether physicians are likely to change their oncologic clinical practice after receiving a detailed communication of their patients' preferences of adverse events.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Greater than or equal to 19 years of age
* Diagnosed with stage IV non-small cell lung cancer (NSCLC)
* Able to understand spoken English
* Eligible to undergo chemotherapy for stage IV NSCLC, to include, but not limited to, those who:
1. have not yet started chemo
2. are currently undergoing chemo for stage IV NSCLC
3. have completed first line stage IV NSCLC chemo or progressed to maintenance for stage IV NSCLC within the last 30 days
4. elect to have chemo elsewhere -- not at one of the study sites
5. decline chemo
Exclusion Criteria
* Not willing and/or able to provide consent
* Not able to understand spoken English
* Not eligible to undergo chemotherapy for stage IV NSCLC
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Patient-Centered Outcomes Research Institute
OTHER
University of Nebraska
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
KM Islam, PhD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
KM Munirul Islam, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Nebraska
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moffitt Cancer Center
Tampa, Florida, United States
Kansas City VA Medical Center
Kansas City, Missouri, United States
Saint Francis Cancer Treatment Center
Grand Island, Nebraska, United States
Southeast Nebraska Cancer center
Lincoln, Nebraska, United States
Callahan Cancer Center of Great Plains Regional Medical Center
North Platte, Nebraska, United States
Nebraska-Western Iowa (NWI) VA Health Care System
Omaha, Nebraska, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Patient Centered Outcomes Research Institute
University of Nebraska Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
318-13-EP
Identifier Type: -
Identifier Source: org_study_id